The Importance of Acute Hypertensive Response in ICH
2013; Lippincott Williams & Wilkins; Volume: 44; Issue: 6_suppl_1 Linguagem: Inglês
10.1161/strokeaha.111.000758
ISSN1524-4628
Autores Tópico(s)Acute Ischemic Stroke Management
ResumoHomeStrokeVol. 44, No. 6_suppl_1The Importance of Acute Hypertensive Response in ICH Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBThe Importance of Acute Hypertensive Response in ICH Adnan I. Qureshi, MD Adnan I. QureshiAdnan I. Qureshi From the Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN. Originally published1 Jun 2013https://doi.org/10.1161/STROKEAHA.111.000758Stroke. 2013;44:S67–S69Acute hypertensive response is the elevation of blood pressure (BP) above normal and premorbid values that initially occurs within the first 24 hours of symptom onset in patients with intracerebral hemorrhage (ICH).1 The acute hypertensive response is characterized by its high prevalence, self-limiting nature, and prognostic significance. To remain consistent with the 2003 World Health Organization/International Society of Hypertension statement,2 acute hypertensive response is defined as systolic BP (SBP)≥140 mm Hg demonstrated on 2 recordings taken 5 minutes apart within 24 hours of symptom onset. A total of 33 992 patients (75.0%) had an initial SBP≥140 mm Hg among 45 330 patients presenting with an ICH analyzed in the National Hospital Ambulatory Medical Care Survey.3 Acute hypertensive response is usually set on the platform of inadequately treated or undetected chronic hypertension. However, elevation and spontaneous reduction in the initial BP during the next few days support the role of other transient and stroke-specific mechanisms. Presumably, the primary cause of the acute hypertensive response is damage or compression of specific regions in the brain that mediate autonomic control with functional adaptation during the next few days.4,5 Hypertensive responses to other factors are exaggerated and additive because of impaired parasympathetic activity and baroreceptor sensitivity.6 This article addresses the state of knowledge about acute therapy for hypertensive response with ICH.The treatment of acute hypertensive response in ICH has been controversial for the past 3 decades. The Figure demonstrates the 4 periods of evolution in our understanding of pathophysiology and treatment. The current notion of treatment is based on the observation that one third of the subjects presenting with ICH demonstrate hematoma expansion (with subsequent deterioration and death) in the first few hours after onset.7 An initial SBP of ≥200 mm Hg is associated with hematoma expansion, perihematoma brain edema formation,8 and increased mortality9 among patients with an ICH. Recent studies suggest that reduced metabolism (hibernation)10 and preserved autoregulation in the perihematoma region11 may prevent any ischemic injury associated with SBP reduction. The current American Stroke Association12 and European Stroke Initiative13 guidelines recommend reduction and maintenance of SBP<180 mm Hg in patients with an ICH. A lower limit for safe reduction is undefined. Both guidelines acknowledge that there may be a subset of patients who can tolerate more aggressive SBP reduction, such as those with good neurological status or without chronic hypertension.Download figureDownload PowerPointFigure. Evolution of understanding on acute hypertensive response in patients with intracerebral hemorrhage (ICH). BP indicates blood pressure.Treatment of acute hypertensive response has been subsequently incorporated as 1 of the 26 quality indicators related to 18 facets of care to quantify the appropriateness of medical care.14 The ICH-specific intensity of care quality metrics14 includes treatment with intravenous antihypertensive medication for 24 hours after Emergency Department arrival for elevated BP (SBP≥180 mm Hg) as a quality parameter on the basis of its high prevalence and guidelines from professional organizations. The performance is scored as 1, if SBP target goal is reached within 2.5 hours of the second of the 2 consecutive measurements or not applicable, and 0, if SBP target range is not achieved. Treatment success is defined as target BP range achieved within 2.5 hours of elevated BP detection (on the basis of the time interval between 2 consecutive SBP≥180 mm Hg and first SBP<180 mm Hg recordings). Actual lowering of SBP and not the treatment goal specified was chosen because actual lowering is associated with lower rates of hematoma expansion and death and disability at 3 months in a previous study.15 SBP was used to define treatment target because the present evidence supports the association between SBP and hematoma expansion.16 No clear relationship with diastolic BP has been demonstrated. Interestingly, SBP in patients with an ICH demonstrates greater variability and large magnitude changes with less prominent changes in diastolic BP.17 Thus, both diastolic BP and mean arterial pressure may underestimate dynamic changes in BP in the first 24 hours of ICH. The quality metrics recommend adequate SBP control with an infusion for 24 hours after initiation of treatment (24–27 hours after symptom onset), to provide adequate SBP control during the time that hematoma expansion will mostly occur. Although the rate of hematoma expansion is highest in the first 3 hours after symptom onset,18 expansion occurs in 12% to 37% of patients between 3 and 24 hours after symptom onset. Early termination of antihypertensive treatment may lead to poor control of SBP, with subsequent increase in delayed bleeding. In a validation study, the score on intensity of care quality metrics in 50 consecutive patients with an ICH ranged from 17 to 26 points.19 Survival of patients with an ICH was different in tertiles on the basis of the performance score with highest survival among tertile of highest score on the intensity of care quality metrics (100%, 67%, and 55%; P=0.017). The receiver operator curve demonstrated a high discriminating ability of intensity of care quality metrics for in-hospital mortality (receiver operator curve value, 0.73; 95% confidence interval, 0.6–0.87). In an exploratory analysis, we adjusted for age, hematoma volume, initial Glasgow Coma Scale score, and intraventricular hemorrhage. After adjusting for markers of disease severity, higher total score on ICH-specific intensity of care quality metrics continued to demonstrate a relationship with lower in-hospital mortality (odd ratio, 0.72; 95% confidence interval, 0.48–1.06). However, further studies will be required to determine whether intensity of care or relative lack of response to treatment because of severity of disease accounts for this relationship. The current preliminary data support SBP treatment as a valuable part of intensity of care among patients with an ICH independent of markers of disease severity.More aggressive SBP lowering was initially considered because an observational study suggested that more aggressive SBP reduction may have greater benefit in reducing the rate of hematoma expansion.20 The rate of hematoma expansion was 9% in patients with SBP<150 mm Hg and 30% among patients treated to maintain SBP<160 mm Hg or a higher threshold. The National Institute of Neurological Disorders and Stroke–funded Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)21 trial was a multicenter open-labeled pilot trial to determine tolerability and safety of 3 escalating levels of antihypertensive treatment goals for acute hypertensive response in 60 subjects with supratentorial ICH within 6 hours of symptom onset. The observed proportions of neurological deterioration and serious adverse events were below the prespecified safety thresholds, and the 3-month mortality rate was lower than expected in all SBP tiers, including the most aggressive treatment tier (to reduce and maintain SBP<140 mm Hg).22 The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage (INTERACT) study was an investigator initiated, blinded outcome, randomized trial that randomized 404 patients with ICH23 with elevated SBP (≥150 and <220 mm Hg) to either intensive BP management (SBP<140 mm Hg) or American Stroke Association-guideline–based BP management (SBP<180 mm Hg) using available antihypertensive agents. Relative risk of hematoma growth ≥33% or ≥12.5 mL was 36% lower in the intensive group than in the American Heart Association-guideline–based BP management group. In subgroup analyses, patients recruited within 3 hours and patients with an initial SBP≥181 mm Hg seemed to have the greatest benefit with intensive SBP reduction.After the ATACH I trial22 proved the feasibility and tolerability of intensive SBP reduction, the INTERACT study23 demonstrated attenuation of hematoma expansion with intensive SBP reduction, 2 phase III trials were initiated. In the last quarter of 2007, the INTERACT phase III was initiated that combined the data derived from the vanguard phase and the main phase to perform the final analysis with adequate power. The trial recruited 2800 patients with acute ICH from ≈140 centers. The data are being analyzed and anticipated to be published in 2013. The primary objective of the ATACH II14,24 initiated in 2010 was to determine the efficacy of intensive BP reduction for acute hypertensive response in 1280 subjects with supratentorial ICH. The primary hypothesis of the trial is that intensive SBP reduction (SBP 10% compared with standard BP reduction (SBP<180 mm Hg) among patients with ICH treated within 4.5 hours of symptom onset. The ATACH II will provide critically unique information to address whether the benefit or lack of benefit is either augmented or unchanged in patients treated within 4.5 hours, those with SBP≥180 mm Hg, or those treated with a single agent and achieving target SBP at a high rate. The ATACH study will also provide information about any differential effect between populations, or because of overall intensity of care or threshold for treatment.The results of the ongoing studies will have direct implications for 75% of the patients with ICH. SBP treatment is a strategy that can be made widely available without specialized equipment or personnel, and can make a major impact on outcome in patients with ICH. In a post hoc analysis of ATACH I, we evaluated the effect of SBP reduction (relative to initial SBP) on poor 3-month outcome (defined as a modified Rankin scale score of 4–6) to derive estimates of treatment benefit.15 The median SBP reduction was 62 mm Hg at 6 hours from treatment initiation. The frequency of poor 3-month outcome was 48% versus 35% in patients having less (<62 mm Hg) versus equal to or more than the median SBP reduction (≥62 mm Hg) at 6 hours (absolute reduction of 13%). The lower rate of poor outcome at 3 months was probably attributed to the lower rate of hematoma expansion in patients with SBP reduction of ≥62 mm Hg (median value) at 6 hours from treatment (21% versus 31%, a 10% absolute reduction). A prominent reduction in morbidity and mortality may be possible if estimates of treatment effect from our current pilot trial are accurate.DisclosuresDr Qureshi has received funding from the National Institutes of Health RO1-NS44976-01A2 (medication provided by ESP Parma), American Heart Association Established Investigator Award 0840053N, National Institute of Health U01-NS062091-01A2, and the Minnesota Medical Foundation, Minneapolis, MN.FootnotesCorrespondence to Adnan I. Qureshi, MD, University of Minnesota, MMC 295, 420 Delaware St SE, Minneapolis, MN 55455. E-mail [email protected]References1. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management.Circulation. 2008; 118:176–187.LinkGoogle Scholar2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.J Hypertens. 2003; 21:1983–1992.CrossrefMedlineGoogle Scholar3. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Hussein HM, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States.Am J Emerg Med. 2007; 25:32–38.CrossrefMedlineGoogle Scholar4. Barron SA, Rogovski Z, Hemli J. Autonomic consequences of cerebral hemisphere infarction.Stroke. 1994; 25:113–116.LinkGoogle Scholar5. Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex.Neuroreport. 2004; 15:357–361.CrossrefMedlineGoogle Scholar6. Robinson TG, James M, Youde J, Panerai R, Potter J. Cardiac baroreceptor sensitivity is impaired after acute stroke.Stroke. 1997; 28:1671–1676.LinkGoogle Scholar7. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.Neurology. 2006; 66:1175–1181.CrossrefMedlineGoogle Scholar8. Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A, Kotsis V, et al. Association between 24-h blood pressure monitoring variables and brain oedema in patients with hyperacute stroke.J Hypertens. 2003; 21:2167–2173.CrossrefMedlineGoogle Scholar9. Dandapani BK, Suzuki S, Kelley RE, Reyes-Iglesias Y, Duncan RC. Relation between blood pressure and outcome in intracerebral hemorrhage.Stroke. 1995; 26:21–24.LinkGoogle Scholar10. Kim-Han JS, Kopp SJ, Dugan LL, Diringer MN. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage.Stroke. 2006; 37:2457–2462.LinkGoogle Scholar11. Powers WJ, Zazulia AR, Videen TO, Adams RE, Yundt KD, Aiyagari V, et al. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage.Neurology. 2001; 57:18–24.CrossrefMedlineGoogle Scholar12. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES, et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2010; 41:2108–2129.LinkGoogle Scholar13. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, et al. Recommendations for the management of intracranial haemorrhage—part i: spontaneous intracerebral haemorrhage. The European stroke initiative writing committee and the writing committee for the EUSI executive committee.Cerebrovasc Dis. 2006; 22:294–316CrossrefMedlineGoogle Scholar14. Qureshi AI. Intracerebral hemorrhage specific intensity of care quality metrics.Neurocrit Care. 2011; 14:291–317.CrossrefMedlineGoogle Scholar15. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, et al; Antihypertensive Treatment of Acute Cerebral Hemorrhage Study Investigators. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study.Arch Neurol. 2010; 67:570–576.CrossrefMedlineGoogle Scholar16. Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. Predisposing factors to enlargement of spontaneous intracerebral hematoma.Stroke. 1997; 28:2370–2375.LinkGoogle Scholar17. Morfis L, Schwartz RS, Poulos R, Howes LG. Blood pressure changes in acute cerebral infarction and hemorrhage.Stroke. 1997; 28:1401–1405.LinkGoogle Scholar18. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course.Stroke. 1996; 27:1783–1787.LinkGoogle Scholar19. Qureshi AI, Majidi S, Chaudhry SA, Qureshi MH, Suri MF. Validation of intracerebral hemorrhage-specific intensity of care quality metrics.J Stroke Cerebrovasc Dis. Published online May 24, 2012.Google Scholar20. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement.Stroke. 2004; 35:1364–1367.LinkGoogle Scholar21. Qureshi AI. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH): rationale and design.Neurocrit Care. 2007; 6:56–66.CrossrefMedlineGoogle Scholar22. Antihypertensive treatment of acute cerebral hemorrhage (ATACH) investogators.Crit Care Med. 2010; 38:637–648CrossrefMedlineGoogle Scholar23. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.Lancet Neurol. 2008; 7:391–399.CrossrefMedlineGoogle Scholar24. Sato S, Yamamoto H, Qureshi AI, Palesch YY, Toyoda K. Antihypertensive treatment of acute cerebral hemorrhage (ATACH)-II at Japan site: study design and advance construction of domestic research network.Rinsho Shinkeigaku. 2012; 52:642–650CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByGreenberg S, Ziai W, Cordonnier C, Dowlatshahi D, Francis B, Goldstein J, Hemphill J, Johnson R, Keigher K, Mack W, Mocco J, Newton E, Ruff I, Sansing L, Schulman S, Selim M, Sheth K, Sprigg N and Sunnerhagen K (2022) 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association, Stroke, 53:7, (e282-e361), Online publication date: 1-Jul-2022. Liu D, Zhang G, Wang Y, Li J, Cao P, Yin X, Zhou C and Wang M (2022) Geometric features of middle cerebral artery are associated with spontaneous basal ganglia intracerebral haemorrhage, Stroke and Vascular Neurology, 10.1136/svn-2021-001277, (svn-2021-001277) Giraldo M and Botero L (2022) Neurological Complications of Anticoagulation Transfusion Practice in Clinical Neurosciences, 10.1007/978-981-19-0954-2_46, (549-560), . DeWitt K and Porter B (2021) Emergency Neuropharmacology, Emergency Medicine Clinics of North America, 10.1016/j.emc.2020.09.008, 39:1, (133-154), Online publication date: 1-Feb-2021. Lim B, Lee W, Ng W, Tay W and Chan W (2021) Benefits and safety of transdermal glyceryl trinitrate in acute stroke: a systematic review and meta-analysis of randomised trials (protocol), BMJ Open, 10.1136/bmjopen-2020-043591, 11:1, (e043591), Online publication date: 1-Jan-2021. Nagai M, Dote K and Kato M (2021) Autonomic response after hemorrhagic stroke in the right insular cortex: What is the common pathophysiology in rat and human?, Autonomic Neuroscience, 10.1016/j.autneu.2020.102755, 230, (102755), Online publication date: 1-Jan-2021. Andalib S, Lattanzi S, Di Napoli M, Petersen A, Biller J, Kulik T, Macri E, Girotra T, Torbey M and Divani A (2020) Blood Pressure Variability: A New Predicting Factor for Clinical Outcomes of Intracerebral Hemorrhage, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2020.105340, 29:12, (105340), Online publication date: 1-Dec-2020. Qureshi A, Huang W, Lobanova I, Hanley D, Hsu C, Malhotra K, Steiner T, Suarez J, Toyoda K and Yamamoto H (2020) Systolic Blood Pressure Reduction and Acute Kidney Injury in Intracerebral Hemorrhage, Stroke, 51:10, (3030-3038), Online publication date: 1-Oct-2020. Jafari M and Damani R (2020) Blood pressure variability and outcome after acute intracerebral hemorrhage, Journal of the Neurological Sciences, 10.1016/j.jns.2020.116766, 413, (116766), Online publication date: 1-Jun-2020. Allison T, Bowman S, Gulbis B, Hartman H, Schepcoff S and Lee K (2017) Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Patients With Stroke, Journal of Intensive Care Medicine, 10.1177/0885066617724340, 34:11-12, (990-995), Online publication date: 1-Nov-2019. Zhang L, Li J, Yin K, Jiang Z, Li T, Hu R, Yu Z, Feng H and Chen Y (2019) Computed tomography angiography-based analysis of high-risk intracerebral haemorrhage patients by employing a mathematical model, BMC Bioinformatics, 10.1186/s12859-019-2741-5, 20:S7, Online publication date: 1-May-2019. Haller J, Wiss A, May C, Jones G and Smetana K (2019) Acute Management of Hypertension Following Intracerebral Hemorrhage, Critical Care Nursing Quarterly, 10.1097/CNQ.0000000000000247, 42:2, (129-147), Online publication date: 1-Apr-2019. Zhang X, Zhou S, Zhang Q, Fu X, Wu Y, Liu J, Liang B, Yang Z and Wang X (2019) Stereotactic aspiration for hypertensive intracerebral haemorrhage in a Chinese population: a retrospective cohort study, Stroke and Vascular Neurology, 10.1136/svn-2018-000200, 4:1, (14-21), Online publication date: 1-Mar-2019. Qureshi A and Qureshi M (2017) Acute hypertensive response in patients with intracerebral hemorrhage pathophysiology and treatment, Journal of Cerebral Blood Flow & Metabolism, 10.1177/0271678X17725431, 38:9, (1551-1563), Online publication date: 1-Sep-2018. Mustanoja S, Putaala J, Koivunen R, Surakka I and Tatlisumak T (2018) Blood pressure levels in the acute phase after intracerebral hemorrhage are associated with mortality in young adults, European Journal of Neurology, 10.1111/ene.13662, 25:8, (1034-1040), Online publication date: 1-Aug-2018. Arboix A (2018) Hypertension and the acute phase of intracerebral haemorrhage: more evidence of the 'silent killer', European Journal of Neurology, 10.1111/ene.13640, 25:8, (1007-1008), Online publication date: 1-Aug-2018. Qureshi A, Palesch Y, Foster L, Barsan W, Goldstein J, Hanley D, Hsu C, Moy C, Qureshi M, Silbergleit R, Suarez J, Toyoda K and Yamamoto H (2018) Blood Pressure-Attained Analysis of ATACH 2 Trial, Stroke, 49:6, (1412-1418), Online publication date: 1-Jun-2018. Alrahbi S, Alaraimi R, Alzaabi A and Gosselin S (2017) Intensive blood-pressure lowering in patients with acute cerebral hemorrhage, CJEM, 10.1017/cem.2017.35, 20:2, (256-259), Online publication date: 1-Mar-2018. Chung P, Kim J, Sanossian N, Starkmann S, Hamilton S, Gornbein J, Conwit R, Eckstein M, Pratt F, Stratton S, Liebeskind D and Saver J (2018) Association Between Hyperacute Stage Blood Pressure Variability and Outcome in Patients With Spontaneous Intracerebral Hemorrhage, Stroke, 49:2, (348-354), Online publication date: 1-Feb-2018. Appiah K, Minhas J and Robinson T (2018) Managing high blood pressure during acute ischemic stroke and intracerebral hemorrhage, Current Opinion in Neurology, 10.1097/WCO.0000000000000508, 31:1, (8-13), Online publication date: 1-Feb-2018. Hernández-Ortiz O, Torres-López M and Sará-Ochoa J (2018) Manejo intensivo vs. conservador de la presión arterial en pacientes con hemorragia intracerebral aguda: revisión sistemática y metaanálisis, Acta Colombiana de Cuidado Intensivo, 10.1016/j.acci.2017.11.005, 18:1, (1-9), Online publication date: 1-Jan-2018. Shi L, Xu S, Zheng J, Xu J and Zhang J (2017) Blood Pressure Management for Acute Intracerebral Hemorrhage: A Meta-Analysis, Scientific Reports, 10.1038/s41598-017-13111-x, 7:1, Online publication date: 1-Dec-2017. Shi J, Wu G, Zou X and Jiang K (2017) Oleuropein protects intracerebral hemorrhage-induced disruption of blood-brain barrier through alleviation of oxidative stress, Pharmacological Reports, 10.1016/j.pharep.2017.05.004, 69:6, (1206-1212), Online publication date: 1-Dec-2017. Winters M, Martinez J, Mallemat H and Brady W (2017) The critical care literature 2016, The American Journal of Emergency Medicine, 10.1016/j.ajem.2017.07.036, 35:10, (1547-1554), Online publication date: 1-Oct-2017. Majidi S, Suarez J and Qureshi A (2016) Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial, Neurocritical Care, 10.1007/s12028-016-0341-z, 27:2, (249-258), Online publication date: 1-Oct-2017. Mastorakos P, Liu K and Schomer A (2017) Adverse Effects of Aggressive Blood Pressure Control in Patients with Intracerebral Hemorrhage, Journal of Neurocritical Care, 10.18700/jnc.160102, 10:1, (36-40) Inamasu J, Nakae S, Adachi K and Hirose Y (2017) Angiotensin II receptor blockers following intravenous nicardipine administration to lower blood pressure in patients with hypertensive intracerebral hemorrhage, Blood Pressure Monitoring, 10.1097/MBP.0000000000000225, 22:1, (34-39), Online publication date: 1-Feb-2017. Starke R, Peterson E, Komotar R and Connolly E (2016) A Randomized Clinical Trial of Aggressive Blood Pressure Control in Patients With Acute Cerebral Hemorrhage, Neurosurgery, 10.1227/01.neu.0000508604.61565.ba, 79:6, (N17-N18), Online publication date: 1-Dec-2016. Qureshi A, Palesch Y, Barsan W, Hanley D, Hsu C, Martin R, Moy C, Silbergleit R, Steiner T, Suarez J, Toyoda K, Wang Y, Yamamoto H and Yoon B (2016) Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage, New England Journal of Medicine, 10.1056/NEJMoa1603460, 375:11, (1033-1043), Online publication date: 15-Sep-2016. Abdurashitov A, Lychagov V, Sindeeva O, Semyachkina-Glushkovskaya O and Tuchin V (2015) Histogram analysis of laser speckle contrast image for cerebral blood flow monitoring, Frontiers of Optoelectronics, 10.1007/s12200-015-0493-z, 8:2, (187-194), Online publication date: 1-Jun-2015. Yang Z, Zhong S, Liu Y, Shen H and Yuan B (2015) Scavenger receptor SRA attenuates microglia activation and protects neuroinflammatory injury in intracerebral hemorrhage, Journal of Neuroimmunology, 10.1016/j.jneuroim.2014.11.010, 278, (232-238), Online publication date: 1-Jan-2015. June 2013Vol 44, Issue 6_suppl_1 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.111.000758PMID: 23709735 Manuscript receivedJanuary 8, 2013Manuscript acceptedMarch 4, 2013Originally publishedJune 1, 2013 Keywordshypertensionintracerebral hemorrhagestrokeacute hypertensive responseblood pressureclinical trialsPDF download Advertisement SubjectsClinical StudiesIntracranial HemorrhageTreatment
Referência(s)